| Literature DB >> 31680827 |
Albrecht Stroh1,2, Jenny Kressel3,4, Roland Coras5, Antje Y Dreyer6, Wenke Fröhlich6, Annette Förschler3, Donald Lobsien7, Ingmar Blümcke5, Saida Zoubaa8, Jürgen Schlegel8, Claus Zimmer3, Johannes Boltze6,9.
Abstract
Magnetic resonance imaging (MRI) provides a unique tool for in vivo visualization and tracking of stem cells in the brain. This is of particular importance when assessing safety of experimental cell treatments in the preclinical or clinical setup. Yet, specific imaging requires an efficient and non-perturbing cellular magnetic labeling which precludes adverse effects of the tag, e.g., the impact of iron-oxide-nanoparticles on the critical differentiation and integration processes of the respective stem cell population investigated. In this study we investigated the effects of very small superparamagnetic iron oxide particle (VSOP) labeling on viability, stemness, and neuronal differentiation potential of primary human adult neural stem cells (haNSCs). Cytoplasmic VSOP incorporation massively reduced the transverse relaxation time T2, an important parameter determining MR contrast. Cells retained cytoplasmic label for at least a month, indicating stable incorporation, a necessity for long-term imaging. Using a clinical 3T MRI, 1 × 103 haNSCs were visualized upon injection in a gel phantom, but detection limit was much lower (5 × 104 cells) in layer phantoms and using an imaging protocol feasible in a clinical scenario. Transcriptional analysis and fluorescence immunocytochemistry did not reveal a detrimental impact of VSOP labeling on important parameters of cellular physiology with cellular viability, stemness and neuronal differentiation potential remaining unaffected. This represents a pivotal prerequisite with respect to clinical application of this method.Entities:
Keywords: CNS – disorder; MRI; cell tracking; human adult stem cells; magnetic labeling
Year: 2019 PMID: 31680827 PMCID: PMC6797601 DOI: 10.3389/fnins.2019.01092
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1Cell viability of magnetically labeled haNSCs and mESCs (n = 3 with 3 technical replicates each). (A) Trypan blue exclusion test showed no significant differences in viability of three different patient samples (labeling with 0.5 mM). (B) Trypan blue exclusion test 8 and 48 h after labeling showed no decrease in cell viability due to the labeling procedure.
FIGURE 2Cytological analysis of magnetically labeled haNSCs (n = 3 with 3 technical replicates each). (a) Unlabeled control cells and (b) intracytoplasmic VSOP uptake by haNSCs following incubation with 0.5 mM VSOP. (c–f) Cells were fixed with 4% phosphate-buffered saline-buffered paraformaldehyde and intracellular iron was visualized using Prussian blue staining on day 2 as shown in (c,e) and on day 28 as provided in (d,f) after labeling. (g) Cell counting revealed that labeling efficacy at any time point could not be enhanced significantly by lipofection. (h) Proliferation analysis of VSOP-labeled haNSC (1.5 mM) revealed no statistically significant difference in the proliferation abilities of unlabeled haNSC and haNSCs labeled with 0.5 mM VSOP, respectively. Scale bars in (a–f) represent 10 μm. ∗p < 0.01.
FIGURE 3NMR relaxometry and gradient echo MR images of gel phantoms containing haNSCs (n = 3 or more). (a,b) Efficiency of VSOP-labeling was determined after 8 (a) and 48 h (b) using NMR relaxometry. All data were analyzed and presented as mean ± SEM. Differences were considered significant at P < 0.01. (c) Coronal section at gel surface showing two needle tracks as hyperintense signal change. 1 × 103 VSOP labeled haNSCs were injected on the left side; on the right side 1 × 103 unlabeled control haNSCs were injected. (d) Slice 4.5 mm ventral of (c). In the left injection track an area of signal loss can be visualized, due to clusters of magnetically labeled haNSCs. No signal change in the right injection track was observed. (e) Slice 5 mm ventral of (c). The left injection track again shows an area of signal loss, no signal change in the right injection track. (f,g) layer phantoms investigated in 3T SWI MRI. Only 5 × 104 labeled haNSCs were detectable with an imaging protocol being short enough (41:00 min) to be applicable in a hypothetical clinical scenario. ∗p < 0.01.
FIGURE 4Transcriptional and immunohistochemical analysis of stemness and neuronal differentiation (n = 6 to 10). (a) VSOP-labeling and lipofection of non-differentiated stem cells; RT-PCR analysis of pluripotency markers revealed no impact on stemness, and transcribed nestin. 99% of haNSCs expressed the intermediate filament protein nestin, and 65% co-express the nuclear proliferation marker Ki-67. No significant difference between control cells and VSOP labeled haNSCs could be detected. (b–d) show unlabeled control cells, and (e–g) give the VSOP labeled pendant. (h) Nestin expression of haNSCs from three different patients was compared, showing that there is neither a significant difference between patients nor between control cells or labeled cells. (i) 65% of haNSCs co-express nestin and Ki-67, but significant differences between the three patients become apparent. (j) Subsequent neuronal differentiation (n = 6 to 10) resulted in a neuronal phenotype transcribing β-tubulin III, doublecortin, N-CAM1, and MAP-2. Mature mouse hippocampal cells HT22 served as a negative control for pluripotency markers and as a positive control for mature neuronal markers. Scale bars represent 50 μm. ∗p < 0.01.
Expansion and differentiation media.
| Knockout-DMEM and Ham’s F12, 5% knockout serum replacement, 2 mM L-glutamine, 1% penicillin-streptomycin, 1% MEM non-essential amino acids, and 1% N2 supplement (all Invitrogen, Karlsruhe, Germany) | ||||||
| Basic cell culture medium | Basic cell culture medium | Basic cell culture medium | Basic cell culture medium | Knockout-DMEM and Ham’s F12 | haNSC/mESC basic cell culture medium | Expansion medium |
| +10 ng/mL basic fibroblast growth factor (bFGF, Invitrogen) | +2% B-27 supplement | +0.1 mM 2-mercaptoethanol | Embryoid body formation in bacterial dishes for 6 days, final differentiation in gelatine-coated dishes | +1 % ITS supplement (insulin-transferrin-selenium, Invitrogen) | +10% knockout serum replacement | - N2 supplement |
| +10 ng/mL epidermal growth factor (EGF, Invitrogen) | +200 ng/mL sonic hedgehog (SHH) | +15 ng/mL LIF | +10 ng/mL bFGF | - bFGF | ||
| +2.5 μg/mL bovine pituitary extract (BPE, Sigma-Aldrich) | +100 ng/mL fibroblast growth factor-8 (FGF-8) | On mouse fibroblasts (CRL-1503, Sigma) | +20 ng/mL nerve growth factor (NGF) (Invitrogen) | |||
| +15 ng/mL leukemia inhibitory factor (LIF, Sigma-Aldrich) | +2 mM ascorbic acid | +1× B-27 supplement (Invitrogen) | ||||
| +2 μg/mL heparin | ||||||
List of primers.
| Oct4 | 5′- CTCCTGAAGCAGA AGAGGATCAC-3′ | 5′-CTTCTGGCGCCGG TTACAGAACCA-3′ |
| Sox2 | 5′-TGCAGTACAACT CCATGACCA-3′ | 5′-GTGCTGGGACATGT GAAGTCG-3′ |
| nestin | 5′-CAGCGTTGGAACAG AGGTTG-3′ | 5′-GCTGGCACAGG TGTCTCAAG-3′ |
| β3-tubulin | 5′-GCAAGGCCTTCC TGCACT-3′ | 5′-GCGTCCTGGTACT GCTGGTA-3′ |
| DCX | 5′-GACAGCCCACTCT TTTGAGC-3′ | 5′-GCGTAGAGATGGGA GACTGC-3′ |
| NCAM1 | 5′-TATCCCAGTGCCA CGATCTC-3′ | 5′-TGGCTTCCTTGGC ATCATAC-3′ |
| MAP-2 | 5′-GGTGGCAAGGTGC AGATAAT-3′ | 5′-CTTTGGCATTCTCC CTGAAG-3′ |
| ( | ||
| MAP-2 | 5′-GTGGGGGTTGTC ACAGAGG-3′ | 5′-GCTCTCCCAGCG GCAAGG-3′ |
| GAPDH | 5′-CAACGAATTTGGC TACAGCA-3′ | 5′-AGGGGTCTACATG GCAACTG-3′ |